I

Integer Holdings Corporation

Medical device CDMO for cardiac devices

Principal Sales Applications Engineer

Full-TimePosted on 10/15/2026
$128.3k - $188.1k+ Cash-based incentive program + 401(k) match
Expert
Bachelor's, MBA
Remote in USA
Remote
Solution Engineering

About the job

Requirements
  • A Bachelor's degree in a technical field is required.
  • At least 10 years of experience in a technical environment, including at least 10 years related to components or assembly in the medical device industry, is required.
  • In-depth knowledge of product and/or clinical applications in the targeted area of responsibility is required.
  • Ability to operate in a highly regulated business environment is required.
  • Ability to communicate issues and potential resolutions clearly and promptly to customers and internal stakeholders is required.
  • Ability to partner with cross-functional organizations to drive the business is required.
  • Ability to respond to changing priorities with minimal disruption is required.
  • Ability to provide technical leadership in discussions, conference calls, and meetings with customers and staff is required.
  • Ability to read, understand, and interpret technical drawings, models, and schematics is required.
  • Proficiency with Outlook, Excel, Project, Word, and PowerPoint is required.
Responsibilities
  • Evaluate and target profitable new business growth within the Product Category, lead customer-facing technical discussions, manage new business opportunities, and promote company products and capabilities to drive revenue and operating profit growth.
  • Provide technical product support to assigned and new customers within a region or product area, using tools such as technical fairs and forums, aligned with Account and Product Marketing strategies.
  • Own targeted marketing campaigns for new opportunity development as assigned.
  • Work with customers' research and development, product development, and operations teams, along with Global/Key Accounts, Quoting Teams, and manufacturing facilities, to identify, scope, and sell appropriate supply chain solutions.
  • Adhere to company values and applicable safety, environmental, security, quality, regulatory, policy, and operating-procedure requirements, including Quality Management Systems, U.S. Food and Drug Administration regulations, and other regulatory requirements.
  • Initiate the New Business Opportunity review process, define the business rationale for pursuing opportunities, develop business cases with Sales Account and Quoting Teams, and present them to management for consensus and approval.
  • Clarify technical requirements and specifications with customers' technical and engineering teams, translate them into actionable company activities, and screen opportunities with technology experts.
  • Recommend pricing approaches using market-based pricing and price-validation methodologies to support appropriate profitability.
  • Prepare and deliver proposals with Global Sales team members, including pricing and manufacturing strategies and capital and nonrecurring engineering requirements.
  • Represent the organization as the primary technical contact on projects and significant technical matters, coordinate between organizations, and serve as spokesperson on advanced opportunities or programs as needed.
  • Lead technical selling efforts on assigned opportunities and technical discussions promoting company capabilities to new and existing customers.
  • Proactively identify and scope new business opportunities through involvement with customers' research and development, product development, and operations teams.
  • Work with Global and Key Account teams and manufacturing facilities to identify, scope, and sell appropriate supply chain solutions.
  • Execute nondisclosure agreements with customers to protect project confidentiality and intellectual property.
  • Work with Global Account teams to understand customers' business scope and align activities with strategic account plans.
  • Work directly with customers on VIP programs to identify and provide solutions to supply chain management challenges, including design-for-manufacturability requirements.
  • Be responsible for technical and new product development customer satisfaction.
  • Communicate customer concerns across the company and obtain additional assistance when required.
  • Pursue qualified leads from targeted marketing campaigns.
  • Assist in identifying technology trends and market dynamics.
  • Identify capability gaps in market segments and help prioritize development of missing capabilities.
  • Support marketing efforts, including trade shows, as required.
  • Participate in development of the company technology.
  • Comply with work rules concerning safety, health, and the company Quality System.
  • Perform other duties as required.
Desired Qualifications
  • An MBA or advanced degree is preferred.
  • Experience selling to technical contacts at medical device manufacturers is preferred.
  • Previous product and/or clinical experience in CRM, neuromodulation, or vascular markets is preferred.
  • Manufacturing Engineering or Development Engineering experience is preferred.
  • CAD and design-program proficiency is a plus.

About the company

I

Integer Holdings Corporation

View

Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

1940

Get referred to Integer Holdings Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $464.1 million, beating estimates despite weak medtech demand.
  • Integer expects demand recovery after New Ross's July 27-August 10, 2026 shutdown.
  • KKR plans new capacity, technology, and employee ownership after closing by year-end 2026.

What critics are saying

  • Integer withdrew 2026 guidance on August 3, 2026, after KKR announced the buyout.
  • Schall, Brown & Schwartz opened an August 23, 2026 fiduciary-duty investigation.
  • Regulatory or stockholder rejection kills the KKR deal and leaves Integer's weak standalone outlook exposed.

What makes Integer Holdings Corporation unique

  • Integer's R&D Velocity integrates design, prototyping, and manufacturing for complex medtech programs.
  • Its 33-facility global network spans electrophysiology, neuromodulation, and structural heart.
  • KKR's August 3, 2026, $5.7 billion bid validates Integer's scale and customer lock-in.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Adoption Assistance
  • Parental Leave
  • 401(k) Company Match
  • 401(k) Retirement Plan
  • Paid Vacation
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

-1%
Ticker Report
Aug 29th, 2026
Boussard & Gavaudan Gestion Sas Makes New $2.60 Million Investment in Integer Holdings Corporation $ITGR

Boussard & Gavaudan Gestion Sas bought a new position in Integer Holdings Corporation (NYSE:ITGR – Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 28,153 shares of the medical equipment provider’s stock, valued at approximately $2,597,000. Other institutional investors and hedge funds also […]

Yahoo Finance
Aug 16th, 2026
Healthcare stocks outpace S&P 500 by 13 percentage points over six months

Healthcare stocks have returned 26.1% over the past six months, outperforming the S&P 500 by 13.1 percentage points. However, investors must remain cautious due to heavy regulation affecting earnings potential. Integer Holdings faces concerns with 6.1% annual revenue growth over two years, lagging healthcare peers. Its modest revenue base of $1.84 billion provides less fixed cost leverage than larger competitors. The company trades at $125.07 per share, or 18.6 times forward price-to-earnings. Evolent Health shows weak platform performance and declining returns on capital. Its high net-debt-to-EBITDA ratio of 7 times could force unfavourable capital raises if market conditions worsen. Shares trade at $4.15, representing 12.4 times forward price-to-earnings. Tenet Healthcare, operating hospitals and surgical centres across nine US states, emerges as the recommended healthcare investment.

Yahoo Finance
Aug 4th, 2026
Integer Holdings acquired by KKR for $5.7B in all-cash deal at $127 per share

Integer Holdings agreed to be acquired by private equity firm KKR in an all-cash deal valued at approximately $5.7 billion. The transaction values the medical technology company at $127 per share. Shares jumped 2.7% in afternoon trading, continuing a rally from the previous session when the stock surged over 20% following the announcement. The acquisition news overshadowed strong second-quarter results, where Integer posted an adjusted profit of $1.60 per share on $464.1 million in revenue, surpassing analyst estimates. Following the buyout announcement, Integer withdrew its previously issued financial guidance and cancelled its upcoming earnings conference call. Shares traded at $124.50, marking a new 52-week high.

BizWire Express
Aug 3rd, 2026
KKR to acquire Integer for $5.7B in all-cash deal at $127 per share

KKR has agreed to acquire Integer Holdings Corporation, a medical device contract development and manufacturing organisation, in an all-cash transaction valued at approximately $5.7 billion. Integer stockholders will receive $127 per share, representing a 51.8% premium to the company's closing share price on 29 April 2026. The acquisition follows a comprehensive strategic review announced by Integer in April 2026. The Integer Board unanimously approved the agreement and recommends stockholder approval. KKR plans to invest in Integer's capacity, technology, innovation, and talent. The firm also intends to establish a broad-based employee ownership programme following the transaction's close, consistent with its approach across portfolio companies. The transaction is expected to close by year-end, subject to stockholder approval and regulatory clearances. Upon completion, Integer will become privately held and delist from the New York Stock Exchange.

Yahoo Finance
Aug 3rd, 2026
Integer Holdings beats Q2 expectations with $464M revenue and $1.60 earnings per share

Integer Holdings Corp. reported second-quarter net income of $23.6 million, or 69 cents per share. Adjusted earnings came to $1.60 per share, exceeding Wall Street expectations of $1.38 per share. The Plano, Texas-based medical device outsource manufacturer posted revenue of $464.1 million for the period, also beating analyst forecasts of $452.5 million. The results surpassed predictions from five analysts surveyed by Zacks Investment Research on both earnings and revenue metrics.